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Summary Multi-drug resistant falciparum malaria is widespread in Asia. In Thailand, Cambodia and Vietnam the
national protocols have changed largely to artesunate combined treatment regimens but elsewhere in
East and South Asia chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) are still widely
recommended by national malaria control programmes. In Kachin State, northern Myanmar, an area of
low seasonal malaria transmission, the efﬁcacy of CQ (25 mg base/kg) and SP (1.25/25 mg/kg), the
nationally recommended treatments at the time, were compared with meﬂoquine alone (M; 15 mg base/
kg) and meﬂoquine combined with artesunate (MA; 15:4 mg/kg). An open randomized controlled trial
enrolled 316 patients with uncomplicated Plasmodium falciparum malaria, stratiﬁed prospectively
into three age-groups. Early treatment failures (ETF) occurred in 41% (32/78) of CQ treated patients
and in 24% of patients treated with SP (18/75). In young children the ETF rates were 87% after CQ and
35% after SP. Four children (two CQ, two SP) developed symptoms of cerebral malaria within 3 days
after treatment. By day 42, failure rates (uncorrected for reinfections) had increased to 79% for CQ
and 81% for SP. ETF rates were 2.5% after treatment with M and 3.9% after treatment with MA
(P > 0.2). Overall uncorrected treatment failure rates at day 42 following M and MA were 23% and
21%, respectively. Chloroquine and SP are completely ineffective for the treatment of falciparum
malaria in northern Myanmar. Meﬂoquine treatment is much more effective, but three day combination
regimens with artesunate will be needed for optimum efﬁcacy and protection against resistance.
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Introduction
Although multi-drug resistant Plasmodium falciparum
malaria is generally regarded as a South-east Asian
problem (Singhasivanon 1999), recent results from
Bangladesh (Rahman et al. 2001), Northeastern India
(Medecins Sans Frontieres-Holland, personal communi-
cation, 2001), Pakistan (Rab et al. 2001), Southern
China (Yang et al. 1997) and Western Myanmar
(Smithuis et al. 1997) all indicate that the problem is
much more widespread throughout the East and South
Asian region. In Myanmar, low-grade resistance to
chloroquine (CQ) appeared in the mid 1970s and
resistance to both CQ and sulfadoxine-pyrimethamine
(SP) has worsened since the 1980s (Aung-Than-Batu
et al. 1975; Tin & Hlaing 1977; Tin et al. 1987). In the
1990s, high levels of resistance to CQ and SP were
reported in West Myanmar (CQ; 82% failure by day 28
and SP; 67% failure by day 28; Smithuis et al. 1997).
In vitro resistance to meﬂoquine (M) has been recorded
in Eastern Myanmar (Wongsrichanalai et al. 2001)
adjacent to the border with Thailand, where it has been
deployed systematically since 1984, but meﬂoquine has
remained effective in Western Myanmar (Smithuis et al.
1997). There are no recent data regarding the situation
of drug resistance in Kachin State in the North of
Myanmar bordering with India and China. In order to
determine the efﬁcacy of current treatment options for
falciparum malaria in Northern Myanmar, to search for
simple single administration alternatives, and thereby
provide an evidence base to support policy change, we
conducted a randomized prospective trial comparing CQ,
sulfadoxine/pyrimethamine, meﬂoquine and a meﬂoqu-
ine-artesunate combination (MA).
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Study site and population
The trial was carried out in the village Sinbo located in the
township of Myitkyina in Kachin State. Kachin State is the
most northern state of the Union of Myanmar, situated
betweenChina(Yunnan)andIndia(Assam).Sinboisasmall
isolated village on the bank of the Irrawaddy river with a
stable population of 6000 people. The village is accessible
only by boat. The area consists of low mountainous forest
and sparsely populated plains, cultivated mainly for rice.
The monsoon season lasts from May to October. Malaria
transmission of P. falciparum (±80%) and P. vivax (±20%)
is low and seasonal. Although detailed entomological data
are unavailable, by comparison with adjacent areas, the
entomological inoculation rate is unlikely to exceed 1
inoculation/person/year.Theﬁrstlinetreatmentprotocolfor
falciparum malaria was CQ or sulfadoxine/pyrimethamine
(SP) in accordance with National Malaria Control Pro-
gramme guidelines at the time of this study (the ﬁrst line
treatment subsequently changed in 2002, see Discussion),
although artesunate and to a lesser extent meﬂoquine were
available through the private sector.
From July to October 1998, all people with complaints
of fever attending the Station Hospital (SH) of Sinbo were
invited to participate in a randomized prospective study
before taking drugs. This was conducted by doctors and
microscopists from Artsen zonder Grenzen (Medecins Sans
Frontieres-Holland) in co-operation with the SH staff. The
study protocol was approved by the health authorities of
Kachin State.
Study procedures
A blood smear was prepared from all patients presenting
with an axillary temperature ‡37.5  C or a history of fever
within the past 2 days. To avoid enrolling patients with
asymptomatic parasitaemia, patients were included only if
they had fever or history of fever and a parasite density of
more than 1000 asexual P. falciparum parasites per mm
3.
Parasite density was calculated relative to 500 leucocytes in
the thick blood smear stained with Giemsa (pH 7.2),
assuming a standard whole blood leucocyte count of
8000/mm
3. Children with a body weight of less than 5 kg,
pregnant women, patients with signs and symptoms
suggestive of complicated malaria (World Health
Organization and Control of Tropical Diseases 1990) or
suggestive of another cause for fever, and patients with a
recent history of meﬂoquine use were excluded from
entering the study. Patients with a parasite count
>250 000/mm
3 or with a mixed infection were also
excluded.
Patients were enrolled in the study only after full
informed consent was obtained from them or from their
parents or guardians. The patient was then interviewed
and examined and a symptom questionnaire was com-
pleted in each case. The patients were stratiﬁed pro-
spectively in three age groups (<5, 5–14 and ‡15 years)
and were allocated randomly to one of four treatment
arms:
• CQ: chloroquine (Pharmamed, Valetta Malta) 10 mg
base/kg on day 0 and 1, 5 mg/kg on day 2.
• SP: sulfadoxine/pyrimethamine (Pharmamed); single
dose: 25 and 1.25 mg/kg, respectively.
• M: meﬂoquine (Eloquine; Medochemie Ltd, Limassol,
Cyprus); single dose: 15 mg base/kg.
• MA: meﬂoquine 15 mg base/kg + artesunate (Guilin
Pharmaceutical Works, Guangxi, China); single dose:
4 mg/kg.
All dosages were single and supervised, except for
patients from the CQ group, who had to return on day 1
and 2 for supervised drug administration to complete the
3 day treatment regimen. Patients with an axillary tem-
perature over 38  C were given paracetamol (15 mg/kg). If
the patient vomited within 30 min the full dose was
repeated. If vomiting occurred after 30 min but within the
hour, half the dose was repeated.
Patients were seen on day 0, 3, 7, 14, 21, 28, 35 and
42 and they were invited to come at any other time they
felt sick and/or when fever developed. In the ﬁrst
2 weeks of follow-up clinical symptoms and temperature
were recorded, and on all follow-up dates a malaria
blood ﬁlm was prepared. On day 0 and day 3 the
parasite density was also checked. The haemoglobin
concentration was measured on enrollment and on day
14.
Therapeutic response was deﬁned using a combination
of clinical and parasitological criteria: Early treatment
failure £ day 3: persistent fever on day 3 plus presence of
P. falciparum in the blood smear, or a parasite density on
day 3 ‡25% of parasite density on day 0, or clinical
deterioration up to day 3 in the presence of parasites.
Intermediate treatment failure day 4–14: reappearance
of fever on any day between day 4 and day 14 plus a
positive blood ﬁlm for P. falciparum.
Late treatment failure day 15–42: positive blood ﬁlm
for P. falciparum between day 15 and day 42, with or
without fever. This includes both recrudescences and
reinfections, but given the low transmission in the area,
less than 15% of recurrent parasitaemias within the
42-day follow-up period would be expected to be new
infections even taking into account seasonality of trans-
mission.
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All patients with treatment failures following CQ or SP
received MA (15 and 4 mg/kg, respectively) in a single
dose. Patients with treatment failures after M or MA
were given treatment with artesunate (2 mg/kg/day) for
7 days.
Statistical analysis
With a sample size of 78 patients per treatment arm, a
difference in treatment failure rate of 50% vs. 25% could
be detected with 80% power and 95% conﬁdence, taking
into account a drop out rate of up to 20%.
Data were analysed using SPSS for Windows (SPSS
Software, Gorinchem, The Netherlands) and EpiInfo,
version 6 (CDCP, Atlanta, GA, USA). Continuous data
were analysed by Student’s t-test or anova. Proportions
and categorical data were compared by chi-square test with
Yates’, correction or by two-tailed Fisher’s exact test.
Results
Between July and August 1998, 317 patients with
uncomplicated falciparum malaria were recruited. One
patient withdrew after day 0 and was excluded from the
analyses. Ten patients withdrew during follow-up. All of
them had initially cleared their parasitaemias. Twelve
patients (4%) became positive for P. vivax during the
follow up period, all after day 14 (CQ, 1; SP, 5; MQ, 2;
MA, 4). Nine of these were withdrawn from further
follow-up as they received CQ treatment again before day
42. The other three presented with P. vivax infections on
day 42. All data of patients are included in the analysis for
the period they participated (Figure 1).
Baseline admission clinical and laboratory variables are
shown in Table 1 and did not differ signiﬁcantly among the
four treatment groups. The geometric mean parasite
density on admission was signiﬁcantly lower in the younger
age groups than in the older age group (P < 0.001).
Clinical and parasitological responses
Early failures (£ 3 days). No patient died, but four
patients, all aged under 5 years, developed cerebral malaria
within 3 days. Two had received CQ and the other two
had received SP as initial treatment. All survived after
treatment with intramuscular artemether. On day 3, 32%
(24/76) of patients in the CQ group and 27% (20/74) of
patients in the SP group were still febrile. These rates were
much lower for patients from the M (9%) and MA (12%)
groups (P < 0.0001, RR ¼ 2.8, 95% CI 1.7–4.8)
(Figure 2). Of the 76 patients who received CQ and 73
patients who received SP 41 (54%) and 27 (37%),
respectively, had not cleared their parasites by day 3. These
rates were 13% (10/80) and 5% (4/76), respectively, after
receiving M and MA (P < 0.0001, RR ¼ 5.1 95% CI 3.0–
8.6). Early failure rates (within 3 days) were 32 of 78
(41%), 18 of 75 (24%), two of 80 (3%), and three of 76
(4%) in the CQ, SP, M and MA groups, respectively
(P < 0.0001). The early failure rate of the CQ group was
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Figure 1 Comparison of failure rates on day 3 stratiﬁed by
age.
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Figure 2 Comparison of responses to treatment of falciparum
malaria with chloroquine (CQ), sulfadoxine/pyrimethamine (SP),
meﬂoquine (M) and meﬂoquine plus artesunate (MA).
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RR ¼ 1.71, 95% CI 1.1–2.8). Patients from the M and
MA groups had signiﬁcantly less early failures than
patients from the CQ (P < 0.0001, RR ¼ 12.8, 95% CI
5.2–31.6) and the SP group (P < 0.0001, RR ¼ 7.5, 95%
CI 2.9–19.4) (Table 2). Children under 5 years of age had
an early failure rate of 87% (13/15) after CQ and 33% (6/
18) after SP (P ¼ 0.006), while after the M and MA group
there were no early failures in this age group. Early failure
was closely related to age in the CQ group (Figure 1). The
youngest children had higher failure rates after CQ
treatment than the older children (P ¼ 0.052, RR ¼ 1.73,
95% CI 1.09–2.75), and the older children had signiﬁcant
higher failure rates than the adults (P ¼ 0.026, RR ¼ 2.56,
95% CI 1.21–5.42) (Figure 3).
Intermediate failures (4–14 days). Between day 4 and day
14, 35 patients presented again with recurrent
parasitaemia, of whom 17 also had fever and were
deﬁned as failures. Of the remaining 18 patients with
parasitaemia without fever, who continued regular
follow-up, only three patients were a treatment success
at day 42 (two CQ and one M), and 15 failed treatment
(six CQ, seven SP, one M and one MA). Of these 11
Table 1 Admission characteristics of patients with falciparum malaria
CQ SP M MA
Number of patients 79 79 80 78
Age <5 years 15 (19%) 19 (24%) 16 (20%) 15 (19%)
5–14 years 22 (28%) 21 (27%) 24 (30%) 26 (33%)
‡15 years 42 (53%) 39 (49%) 40 (50%) 37 (47%)
Mean age (range) 16.1 (1–54) 17.2 (1–64) 18.2 (1–64) 16.7 (1–51)
Male (%) 61 53 54 47
Haemoglobin (SD) (g/dl) 10.9 (1.8) 10.9 (1.7) 10.8 (1.9) 10.8 (1.7)
Parasite density
a (range) 12 465 (1100–175 000) 13 444 (1200–200 000) 15 837 (1700–230 000) 11 609 (1100–210 000)
Temperature
b (range) 38.4 (36.0–41.1) 38.4 (35.5–41.0) 38.2 (36.0–40.6) 38.2 (35.5–40.5)
a Geometric mean;
b mean.
CQ, chloroquine (25 mg/kg); SP, sulphadoxine-pyrimethamine (1.25/25 mg/kg); M, meﬂoquine (15 mg/kg); MA, meﬂoquine/
artesunate (15/4 mg/kg).
Table 2 Clinical and parasitological outcome indicators on day 3 after treatment
CQ SP M MA
Total 79 79 80 78
Parasitaemic on day 3 41/76 (54%) 27/73 (37%) 10/80 (13%) 4/76 (5%)
Temperature >37.5  C on day 3 24/76 (32%) 20/74 (27%) 7/78 (9%) 9/76 (12%)
Failure rate at day 3 32/78 (41%) 18/75 (24%) 2/80 (3%) 3/76 (4%)
(a) Clinical deterioration 2/78 (3%) 2/75 (3%) 0 0
(b) Parasitaemia >25% of day 0 18/78 (23%) 11/75 (15%) 1/80 (1%) 3/76 (4%)
(c) Fever >37.5  C and parasitaemia 22/78 (28%) 11/75 (15%) 1/80 (1%) 2/76 (3%)
Success on day 3 46/78 (59%) 57/75 (76%) 78/80 (98%) 73/76 (96%)
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Figure 3 Comparison of cumulative failure rates for young
children, older children and adults, after treatment of falciparum
malaria with chloroquine.
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42 were similar for CQ (79%) and SP (81%). M and
MA had comparable overall failure rates (23 and 21%,
respectively) and were signiﬁcantly better than both CQ
and SP (P < 0.0001, RR ¼ 3.7, 95% CI 2.7–5.0)
(Table 3).
Late failures (day 15–42). Failure rates at day 42 were
similar for children under 5 years (56%) and children aged
between 5 and 14 years (58%) but compared with adults,
children had more treatment failures (P ¼ 0.056,
RR ¼ 1.3, 95% CI 1.0–1.6). This difference was only
signiﬁcant for the meﬂoquine group (P ¼ 0.006,
RR ¼ 4.7, 95% CI 1.5–14.9). In the SP group and the MA
group there was no clear relationship between failure
rates and age (Table 3). In this study, we could not
differentiate between recrudescent parasitaemia and new
infections but transmission intensity is low (estimated
EIR < 1 per year) and so the majority of recurrent
infections were probably recrudescences. In order to
estimate the conditional probability of late recurrent
parasitaemia during each week after receiving treatment,
we calculated the proportion of patients with recurrent
parasitaemia per week for patients who still remained in
the study, excluding patients who failed, became positive
for P. vivax, or who dropped out of the study during
previous weeks (Table 4).
Of the patients in the CQ group who were still followed
up during the ﬁfth week, 14% (3/21) had recurrent
parasitaemias, and of the patients who were still followed-
up during the sixth week 20% (four of 20) developed
recurrent parasitaemias. These ﬁgures were 38% (8/21)
and 13% (2/16), respectively, for the SP group.
Anaemia
As a result of the high number of early treatment failures
among patients who received CQ or SP, many patients
could not be assessed for change in haemoglobin on day
14. Of the patients who had not yet failed on day 14, the
haemoglobin concentration increased on average 0.49 g/dl
after CQ, 0.52 g/dl after SP, 0.55 g/l after M and 0.64 after
MA (P ¼ 0.78).
Results of re-treatment
All clinical failures within 14 days after treatment with CQ
or SP, who had no signs of complicated malaria, were
retreated with Meﬂoquine (15 mg/kg) and Artesunate
(4 mg/kg) as a single dose and followed-up for another
6 weeks. All these patients (60) cleared their parasitaemia
before day 7. Of the 57 patients who could be followed-up
weekly for 42 days, 10 (18%) patients had a recurrence of
parasitaemia within 3–6 weeks after retreatment. This
failure rate was similar to the original ﬁrst line MA
treatment group.
Discussion
This study revealed very high levels of clinical and
parasitological resistance to CQ and SP on the northern
Myanmar border. Early failure rates were alarmingly high,
particularly in young children who received CQ (87%).
These ﬁndings are similar to a study done in Western
Myanmar in 1995 (Smithuis et al. 1997), and they conﬁrm
that CQ and SP are not appropriate for the treatment of
Table 3 Cumulative failure rates stratiﬁed by age
Failure rates
Day 3 Day 14 Day 28 Day 42
Chloroquine
Age <5 years 13/15 (87) 13/15 (87) 14/15 (93) 14/15 (93)
Age 5–14 years 11/22 (50) 14/22 (64) 16/20 (80) 18/22 (82)
Age ‡15 years 8/41 (20) 11/40 (28) 24/36 (67) 29/40 (73)
Total 32/78 (41) 38/77 (49) 54/71 (76) 61/77 (79)
Sulfadoxine/pyrimethamine
Age <5 years 6/17 (35) 8/17 (47) 13/17 (76) 15/18 (83)
Age 5–14 years 3/21 (14) 5/21 (24) 13/19 (68) 17/20 (85)
Age ‡15 years 9/37 (24) 12/35 (34) 23/33 (70) 27/35 (77)
Total 18/75 (24) 25/73 (34) 49/69 (71) 59/73 (81)
Meﬂoquine
Age <5 years 0/16 (0) 1/15 (7) 4/15 (27) 4/14 (29)
Age 5–14 years 2/24 (8) 3/23 (13) 5/22 (23) 10/23 (44)
Age ‡15 years 0/40 (0) 0/37 (0) 2/33 (6) 3/37 (8)
Total 2/80 (3) 4/75 (5) 11/70 (16) 17/74 (23)
Meﬂoquine-artesunate
Age <5 years 0/15 (0) 1/14 (7) 1/14 (7) 1/14 (7)
Age 5–14 years 0/26 (0) 1/26 (4) 1/25 (4) 7/25 (28)
Age ‡15 years 3/35 (9) 3/34 (9) 3/33 (9) 7/34 (21)
Total 3/76 (4) 5/74 (7) 5/72 (7) 15/73 (21)
Percentage values are given in parenthesis.
Table 4 The conditional probability of late recurrent
parasitaemia after four treatment regimens
Day 15–21 Day 22–28 Day 29–35 Day 36–42
Chloroquine 9/29 (31) 4/21 (19) 3/21 (14) 4/20 (20)
Sulfadoxine/
pyrimethamine
12/40 (30) 6/24 (25) 8/21 (38) 2/16 (13)
Meﬂoquine 3/65 (5) 3/62 (5) 2/61 (3) 4/61 (7)
Meﬂoquine-
artesunate
0/68 (0) 0/67 (0) 1/65 (2) 9/67 (13)
CQ/SP pooled 21/69 (30) 10/45 (22) 11/42 (26) 6/36 (17)
Percentage values are given in parenthesis.
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convincing recent reports that these drugs continue to work
well anywhere from Pakistan across Northern India and
Bangladesh through to Vietnam.
In this study, we included ‘patients with persistent fever
on day 3 together with P. falciparum in the bloodsmear’ in
the deﬁnition of early failure. This was a precaution based
on a previous ﬁnding in Myanmar that patients with
parasites in the blood on day 3 after CQ or SP, respectively,
97 and 98% would eventually fail (Smithuis et al. 1997).
This policy of caution could have led to overestimation of
the early failure rates. There was a strong correlation
between age and treatment failure after treatment with CQ
and to a lesser extent after meﬂoquine. As in our earlier
study, the early failure rate was signiﬁcantly higher in
children in the CQ treatment group than in adults
(RR ¼ 3.3, 95% CI 1.7–6.5, P ¼ 0.0001). This was not
evident for the other treatment groups. However, meﬂoq-
uine treated children had signiﬁcantly more late treatment
failures than adults (RR ¼ 4.7, CI 1.5–14.9, P ¼ 0.006).
The higher rate of therapeutic failure in children is a
common ﬁnding in endemic areas (ter Kuile et al. 1992;
Smithuis et al. 1997) and presumably reﬂects the lower
level of acquired immunity in children compared with
adults (Mayxay et al. 2001). This emphasizes the import-
ance of assessing the efﬁcacy of antimalarials in all age
groups (stratiﬁed for age). It would be very misleading to
study the efﬁcacy of an ineffective drug such as CQ in
adults only. The duration of follow-up is also critical. A
short follow-up period of the treated patients would have
seriously underestimated the seriousness of resistance.
Resistance to both CQ and SP would have been underes-
timated by almost half, if the follow-up period had been
limited to the WHO 14-day test (World Health Organ-
ization 1996), which, although recommended in high
transmission settings, is also widely used in low transmis-
sion settings such as this. For the more efﬁcacious
meﬂoquine regimen, a 14-day follow-up would have
missed nearly all failures, and even 28 days surveillance
was insufﬁcient for this slowly eliminated drug. Almost
50% of the recurrent infections appeared after 28 days.
Some of the apparent treatment failures will be new
infections and not recrudescences. This would be more
likely among the patients with a late recurrence of
parasitaemia. However, as the study area was a low
transmission setting (estimated EIR < 1), a signiﬁcant
proportion of the recurrent parasitaemias probably
resulted from recrudescent parasitaemias. Meﬂoquine
treatment was much more effective than either CQ or SP,
but already signiﬁcant levels of meﬂoquine resistance are
prevalent in this area. Even a combination of meﬂoquine
(15 mg/kg) and artesunate (4 mg/kg), which has had very
good cure rates in western Myanmar (Smithuis et al.
1997), was associated with a failure rate of 21%. In
contrast to our experience in western Myanmar, in this
study, the addition of a single dose of artesunate, did not
increase efﬁcacy (21% vs. 23%). As the trial did not
include parasite genotyping and most of the meﬂoquine-
artesunate recurrences occurred in the sixth week of
follow-up, we cannot draw deﬁnitive conclusions. But
these results do suggest that the higher dose meﬂoquine
(25 mg/kg) – 3 day artesunate treatment protocols that
have proved highly effective in Thailand (Nosten et al.
2000) should be adopted to ensure high cure rates and to
protect these drugs from further selection of resistant
strains. Such an approach is likely to be cost-effective in the
long-term despite a higher initial outlay on drug costs. The
ﬁndings of this study provided an evidence base to support
a proposal to change to a new ﬁrst line antimalarial
treatment regimen in Myanmar. In 2002, a Committee on
the Development of National Antimalarial Treatment
Policy (for Myanmar) was formed by the Department of
Health to discuss the national protocol for malaria. This
committee endorsed a 3 day meﬂoquine – artesunate
combination regimen (meﬂoquine 15 mg/kg on day 1 and
10 mg/kg on day 2 + artesunate 4 mg/kg on day 0, 1 and
2) as the ﬁrst line treatment for falciparum malaria.
When poor countries do not have enough money for an
effective ﬁrst line treatment for all patients, hard choices
have to be made. In this light, taking into account the
signiﬁcant difference in treatment outcome in different age
groups, it might be an unsatisfactory but pragmatic
compromise to consider different treatment regimens for
different age groups. The failure rate to CQ (and to a lesser
extent to SP) is much higher among children, while they are
more likely to progress to severe malaria. The combination
treatment of meﬂoquine and artesunate is much less
expensive for a child than for an adult.
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